Barrett's Oesophagus and Oesophageal Adenocarcinoma: Time for a New Synthesis

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2010 Jan 23

PMID 20094044

Citations 201

Authors

Brian J Reid

Xiaohong Li

Patricia C Galipeau

Thomas L Vaughan

Affiliations

Soon will be listed here.

Abstract

The public health importance of Barrett's oesophagus lies in its association with oesophageal adenocarcinoma. The incidence of oesophageal adenocarcinoma has risen at an alarming rate over the past four decades in many regions of the Western world, and there are indications that the incidence of this disease is on the rise in Asian populations in which it has been rare. Much has been learned of host and environmental risk factors that affect the incidence of oesophageal adenocarcinoma, and data indicate that patients with Barrett's oesophagus rarely develop oesophageal adenocarcinoma. Given that 95% of oesophageal adenocarcinomas arise in individuals without a prior diagnosis of Barrett's oesophagus, what strategies can be used to reduce late diagnosis of oesophageal adenocarcinoma?

Citing Articles

Biologically targeted discovery-replication scan identifies G×G interaction in relation to risk of Barrett's esophagus and esophageal adenocarcinoma.

Yan L, He Q, Verma S, Zhang X, Giel A, Maj C HGG Adv. 2025; 6(2):100399.

PMID: 39755942 PMC: 11815673. DOI: 10.1016/j.xhgg.2025.100399.

Red dichromatic imaging and linked color imaging as reliable image-enhanced endoscopic procedures for detecting the distal end of the palisade vessels in the columnar metaplastic mucosa of the gastroesophageal junction zone.

Ono S, Yamamoto K, Ishibashi F, Fujimoto A, Urabe Y, Takeda T J Gastroenterol. 2024; 59(8):647-657.

PMID: 38836910 DOI: 10.1007/s00535-024-02118-7.

Multifunctional Ablative Gastrointestinal Imaging Capsule (MAGIC) for Esophagus Surveillance and Interventions.

Park H, Li D, Liang R, Adrales G, Li X BME Front. 2024; 5:0041.

PMID: 38577399 PMC: 10993155. DOI: 10.34133/bmef.0041.

The Role of Long Noncoding RNAs (lncRNAs) in Esophageal Cancer Therapy Resistance and Metastasis.

Weng Z, Hsu S, Wang H, Chen K, Lee P, Chiu C Biomedicines. 2024; 12(3).

PMID: 38540273 PMC: 10967897. DOI: 10.3390/biomedicines12030660.

Molecular Biology and Clinical Management of Esophageal Adenocarcinoma.

Li S, Hoefnagel S, Krishnadath K Cancers (Basel). 2023; 15(22).

PMID: 38001670 PMC: 10670638. DOI: 10.3390/cancers15225410.

References

Barlow W, Orlando R . The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005; 128(3):771-8. DOI: 10.1053/j.gastro.2004.08.014. View

Anderson L, Johnston B, Watson R, Murphy S, Ferguson H, Comber H . Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 2006; 66(9):4975-82. DOI: 10.1158/0008-5472.CAN-05-4253. View

Gatenby P, Ramus J, Caygill C, Shepherd N, Winslet M, Watson A . Routinely diagnosed low-grade dysplasia in Barrett's oesophagus: a population-based study of natural history. Histopathology. 2009; 54(7):814-9. DOI: 10.1111/j.1365-2559.2009.03316.x. View

Yousef F, Cardwell C, Cantwell M, Galway K, Johnston B, Murray L . The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008; 168(3):237-49. DOI: 10.1093/aje/kwn121. View

Galipeau P, Li X, Blount P, Maley C, Sanchez C, Odze R . NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007; 4(2):e67. PMC: 1808095. DOI: 10.1371/journal.pmed.0040067. View

Barrett M, Sanchez C, Prevo L, Wong D, Galipeau P, Paulson T . Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999; 22(1):106-9. PMC: 1559997. DOI: 10.1038/8816. View

Blaser M . Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prev Res (Phila). 2009; 1(5):308-11. DOI: 10.1158/1940-6207.CAPR-08-0170. View

Smith E, De Young N, Pavey S, Hayward N, Nancarrow D, Whiteman D . Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer. 2008; 7:75. PMC: 2567345. DOI: 10.1186/1476-4598-7-75. View

Vakil N, van Zanten S, Kahrilas P, Dent J, Jones R . The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101(8):1900-20. DOI: 10.1111/j.1572-0241.2006.00630.x. View

10.

Mulholland H, Cantwell M, Anderson L, Johnston B, Watson R, Murphy S . Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Causes Control. 2008; 20(3):279-88. DOI: 10.1007/s10552-008-9242-6. View

11.

Ostrowski J, Mikula M, Karczmarski J, Rubel T, Wyrwicz L, Bragoszewski P . Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med (Berl). 2007; 85(7):733-43. DOI: 10.1007/s00109-007-0176-3. View

12.

Samanic C, Chow W, Gridley G, Jarvholm B, Fraumeni Jr J . Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control. 2006; 17(7):901-9. DOI: 10.1007/s10552-006-0023-9. View

13.

El-Serag H, Kvapil P, Hacken-Bitar J, Kramer J . Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol. 2005; 100(10):2151-6. DOI: 10.1111/j.1572-0241.2005.00251.x. View

14.

Bloushtain-Qimron N, Yao J, Shipitsin M, Maruyama R, Polyak K . Epigenetic patterns of embryonic and adult stem cells. Cell Cycle. 2009; 8(6):809-17. DOI: 10.4161/cc.8.6.7938. View

15.

Kubo A, Levin T, Block G, Rumore G, Quesenberry Jr C, Buffler P . Cigarette smoking and the risk of Barrett's esophagus. Cancer Causes Control. 2008; 20(3):303-11. PMC: 2649684. DOI: 10.1007/s10552-008-9244-4. View

16.

Prentice R . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4):431-40. DOI: 10.1002/sim.4780080407. View

17.

van Baal J, Milano F, Rygiel A, Bergman J, Rosmolen W, van Deventer S . A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology. 2005; 129(4):1274-81. DOI: 10.1053/j.gastro.2005.07.026. View

18.

Conio M, Cameron A, Romero Y, BRANCH C, Schleck C, Burgart L . Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut. 2001; 48(3):304-9. PMC: 1760138. DOI: 10.1136/gut.48.3.304. View

19.

Maley C, Galipeau P, Li X, Sanchez C, Paulson T, Blount P . The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 2004; 64(20):7629-33. DOI: 10.1158/0008-5472.CAN-04-1738. View

20.

Rubenstein J, Sonnenberg A, Davis J, McMahon L, Inadomi J . Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc. 2008; 68(5):849-55. PMC: 3481546. DOI: 10.1016/j.gie.2008.02.062. View